ArticleArchives of internal medicine2010
Potential use of 10-year and lifetime coronary risk information for preventive cardiology prescribing decisions: a primary care physician survey.
Article in Archives of internal medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Lifetime risk for cancer death by sex and smoking status: the lifetime risk pooling project.Cancer causes & control : CCC · 2012Pooled it
- Primary care physician use of patient race and polygenic risk scores in medical decision-making.Genetics in medicine : official journal of the American College of Medical Genetics · 2023Trial
- Time-to-event versus ten-year-absolute-risk in cardiovascular risk prevention - does it make a difference? Results from the Optimizing-Risk-Communication (OptRisk) randomized-controlled trial.BMC medical informatics and decision making · 2016Trial
- Providing clinicians with a patient's 10-year cardiovascular risk improves their statin prescribing: a true experiment using clinical vignettes.BMC cardiovascular disorders · 2013Trial
- Evaluating an implementation strategy in cardiovascular prevention to improve prescribing of statins in Germany: an intention to treat analysis.BMC public health · 2013Trial
- Electronic health record-based patient identification and individualized mailed outreach for primary cardiovascular disease prevention: a cluster randomized trial.Journal of general internal medicine · 2013 · on this mapTrial
- Data from a national survey of United States primary care physicians on genetic risk scores for common disease prevention.Data in brief · 2024Article
- A survey of internists' recommendations for aspirin in older adults and barriers to evidence-based use.Journal of thrombosis and thrombolysis · 2022Article
- American Heart Association's Life's Simple 7: Lifestyle Recommendations, Polygenic Risk, and Lifetime Risk of Coronary Heart Disease.Circulation · 2022Article
- Barriers and Facilitators to Using Statins: A Qualitative Study With Patients and Family Physicians.CJC open · 2020Article
- Sex differences in the burden of type 2 diabetes and cardiovascular risk across the life course.Diabetologia · 2019Review
- The Optimizing-Risk-Communication (OptRisk) randomized trial - impact of decision-aid-based consultation on adherence and perception of cardiovascular risk.Patient preference and adherence · 2019Article
- Race-Sex Differences in Statin Use and Low-Density Lipoprotein Cholesterol Control Among People With Diabetes Mellitus in the Reasons for Geographic and Racial Differences in Stroke Study.Journal of the American Heart Association · 2017Observational
- Repeat Cardiovascular Risk Assessment after Four Years: Is There Improvement in Risk Prediction?PloS one · 2016Article
- Race-sex differences in the management of hyperlipidemia: the REasons for Geographic and Racial Differences in Stroke study.American journal of preventive medicine · 2015Article
- Do clinicians recommend aspirin to patients for primary prevention of cardiovascular disease?Journal of general internal medicine · 2015Article
- Headed in the right direction but at risk for miscalculation: a critical appraisal of the 2013 ACC/AHA risk assessment guidelines.Journal of the American College of Cardiology · 2014Review
- Short and lifetime cardiovascular risk estimates: same wine, different bottles. Do we have the COURAGE to abandon risk scores?Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2014Article
- Adding a life-course perspective to cardiovascular-risk communication.Nature reviews. Cardiology · 2013Review
- Stroke risk calculators in the era of electronic health records linked to administrative databases.Stroke · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundData are sparse regarding how physicians use coronary risk information for prescribing decisions.
methodsWe presented 5 primary prevention scenarios to primary care physicians affiliated with an academic center and surveyed their responses after they were provided with (1) patient risk factor information, (2) 10-year estimated coronary disease risk information, and (3) 10-year and lifetime risk estimates. We asked about aspirin prescribing, lipid testing, and lipid-lowering drug prescribing.
resultsOf 202 physicians surveyed, 99 (49%) responded. The physicians made guideline-concordant aspirin decisions 51% to 91% of the time using risk factor information alone. Providing 10-year risk estimates increased concordant aspirin prescribing when the 10-year coronary risk was moderately high (15%) and decreased guideline-discordant prescribing when the 10-year risk was low (2 of 4 cases). Providing the lifetime risk information sometimes increased guideline-discordant aspirin prescribing. The physicians selected guideline-concordant thresholds for initiating treatment with lipid-lowering drugs 44% to 75% of the time using risk factor information alone. Selecting too low or too high low-density lipoprotein cholesterol thresholds was common. Ten-year risk information improved concordance when the 10-year risk was moderately high. Providing lifetime risk information increased willingness to initiate pharmacotherapy at low-density lipoprotein cholesterol levels that were lower than those recommended by guidelines when the 10-year risk was low but the lifetime risk was high.
conclusionsProviding 10-year coronary risk information improved some hypothetical aspirin-prescribing decisions and improved lipid management when the short-term risk was moderately high. High lifetime risk sometimes led to more intensive prescription of aspirin or lipid-lowering medication. This outcome suggests that, to maximize the benefits of risk-calculating tools, specific guideline recommendations should be provided along with risk estimates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.